Gapping up
In reaction to strong earnings/guidance:
- PRTY +27.5%, FCEL +20.8%, PLAY +12.9%, CNC +5.4%, ADBE +4.2%
Other news:
- LPTX +20.6% (receives Oprhan Drug Designation of DKN-01)
- TGI +17.8% (files for $600 mln mixed securities shelf offering)
- RWT +14.5% (rebounding following yesterday's sell off)
- EDIT +11.5% (presents pre-clinical data from a Study of EDIT-301)
- APTO +9.6% (announced that new clinical data on CG-806 was presented in a poster presentation today at the EHA25 Virtual Congress)
- CWH +9.5% (CEO disclosed the purchase of 23.5K shares worth ~$500K)
- JBLU +9.1% (Moody's downgrades senior secured ratings to Ba2)
- AGIO +7.9% (Royalty Pharma acquires rights to Agios' royalty on IDHIFA)
- GNUS +6.4% (announced that its previously filed registration statement on Form S-3, which registers the resale of shares of common stock underlying warrants, was declared effective by the SEC on June 10, 2020)
- BLUE +6.1% (following presentations at EHA Conf)
- QDEL +4.8% (receives BARDA funding to develop point-of-care diagnostic assay that includes COVID-19)
- MYL +3.1% (Mylan N.V. and Biocon receive FDA approval of Semglee)
- VIE +3% (FDA approves Uplizna for NMOSD in adult patients with a particular antibody)
- NVAX +2.5% (details DoD contract)
- LMT +2.1% (awarded $370 mln Navy contract)
Analyst comments:
- PLAY +12.9% (upgraded to Buy from Hold at SunTrust)
- LUV +7.8% (upgraded to Outperform from Neutral at Credit Suisse)
- TTWO +2.3% (upgraded to Buy from Neutral at MKM Partners)